UTI

At a glance

UTI filed 87 disclosures in the last 12 months, including 7 5% holder, 6 insider, 5 issuance and 1 buyback. The most recent key filing was on Oct 29: Issuing 711,989 sh of new shares, equal to 3.3% of existing shares.

Revenue for 2025 was ₩20B, up 7.6% on 2024. It made an operating loss of ₩48.3B. Debt was 227% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩10.3B and operating loss of ₩29.1B.

The 2025 annual report lists 126 employees with an average tenure of 4.9 years and average pay of ₩63.3M, #984 of 2,191 listed companies by average pay. Its 3 directors and auditors were paid ₩247M each on average. It paid no cash dividend for 2025. 박덕영 and related parties held 23.73% at year end.

Of 5 recent 5%+ holder reports, 1 raised and 2 cut a stake; the largest stake reported was 31.89% on Jul 21.

From the 2025 annual report

Staff: 126 (108 men, 18 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩8B. Directors and auditors: 3, paid ₩740M in total.

No cash dividend was paid for 2025.

Largest shareholder

박덕영 holds 16.62%; with 7 related parties the group holds 23.73% of common shares at year end (from 26.91% at the start of the year).

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports